上海科华生物工程股份有限公司 | 证券代码:002022 | | --- | | 债券代码:128124 | 证券代码：002022 证券简称：科华生物 公告编号：2025-041 债券代码：128124 债券简称：科华转债 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届董事会第十五 次会议（以下简称"本次会议"或"会议"）通知于 2025 年 8 月 19 日以邮件方 式送达全体董事、监事及高级管理人员，会议于 2025 年 8 月 22 日以通讯表决的 方式召开。本次会议应参会董事 9 人，实际参会董事 9 人（包含 3 名独立董事）。 本次会议由公司董事长李明先生主持，会议的召开符合《中华人民共和国公司法》、 《上海科华生物工程股份有限公司章程》和《上海科华生物工程股份有限公司董 事会议事规则》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于不向下修正"科华转债"转股价格的议案》 三、备查文件 第十届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经审议，公司董事会决定本次不向下修正" ...

证券代码：002022 证券简称：科华生物 公告编号：2025-042 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于不向下修正"科华转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准上海科华生 物工程股份有限公司公开发行可转换公司债券的批复》（证监许可［2020］970 号） 核准，公司于 2020 年 7 月 28 日公开发行了 738.00 万张可转换公司债券，每张面值 100 元，发行总额 73,800.00 万元。经深圳证券交易所（以下简称"深交所"）"深 证上[2020]731 号"文同意，公司 73,800.00 万元可转债于 2020 年 8 月 20 日起在 深交所挂牌交易，债券简称"科华转债"，债券代码"128124"。 （二）转股价格调整情况 根据有关规定和《募集说明书》的约定，本次发行的可转换公司债券转股期限 自 2021 年 2 月 3 日起可转换为公司股份，可转债的初始转股价格为 21.50 元/股。 2020 ...

格隆汇8月20日丨科华生物(002022.SZ)在互动平台表示，公司目前无针对果蔬、禽类农药残留检测的产 品。但在食品安全领域，公司控股子公司天隆公司可提供的相关检测产品，涵盖非洲猪瘟病毒、金黄色 葡萄球菌、大肠杆菌等食源性病原体检测项目及猪、牛、羊等动物源性成分检测项目。此外，天隆公司 的手持式ATP荧光检测仪及配套试剂，可在10秒内完成环境、物表等ATP（三磷酸腺苷）含量的快速检 测，广泛用于食品加工、餐饮行业等领域，监测清洁及消毒效果，降低交叉污染风险。 ...

Group 1: Convertible Bond Information - The company issued 7.38 million convertible bonds with a total amount of 738 million yuan, and the bonds began trading on August 20, 2020 [2] - The initial conversion price was set at 21.50 yuan per share, with the conversion period from February 3, 2021, to July 27, 2026 [3] - The conversion price has been adjusted multiple times, with the latest adjustment reducing it to 20.64 yuan per share effective from May 10, 2023 [6] Group 2: Price Adjustment Conditions - The company can propose a downward adjustment of the conversion price if the stock price closes below 90% of the current conversion price for at least 10 out of 20 consecutive trading days [7] - The company has a specific procedure for announcing any adjustments, which includes disclosing the decision in a timely manner and holding a shareholder meeting for approval [8] Group 3: Future Price Adjustment Expectations - The period for potential triggering of the price adjustment condition starts from August 11, 2025, and the company has already observed 5 trading days where the stock price closed below the 90% threshold [10] - If the conditions are met, the company will convene a board meeting to decide on the adjustment and will disclose the outcome the next trading day [10] Group 4: New Product Registration - The company has received a medical device registration certificate for in vitro diagnostic reagents from the National Medical Products Administration [11] - This new product registration is expected to enrich the company's product line and positively impact business development, although the future revenue impact remains uncertain [11]

Core Viewpoint - The company, Shanghai Kehua Bio-engineering Co., Ltd., has announced a potential trigger for the downward adjustment of the conversion price of its convertible bonds, "Kehua Convertible Bonds," based on stock performance criteria outlined in its prospectus [2][6]. Group 1: Convertible Bond Basic Information - The company issued 7.38 million convertible bonds with a total value of 738 million yuan, each with a face value of 100 yuan, starting from August 20, 2020 [3]. - The initial conversion price was set at 21.50 yuan per share, with the conversion period running from February 3, 2021, to July 27, 2026 [3]. - The conversion price has been adjusted multiple times due to various corporate actions, with the latest adjustment reducing it to 20.64 yuan per share effective from May 10, 2023 [5]. Group 2: Downward Adjustment Conditions - The company’s board can propose a downward adjustment of the conversion price if the stock price closes below 90% of the current conversion price for at least 10 out of 20 consecutive trading days [6]. - Any proposed adjustment must be approved by at least two-thirds of the voting rights at a shareholders' meeting, excluding those holding the convertible bonds [6]. Group 3: Upcoming Trigger Period - The period for potential triggering of the downward adjustment starts from August 11, 2025, and the company has already observed that the stock price has closed below the conversion price threshold for 5 trading days [7]. - If the conditions are met, the company will hold a board meeting to decide on the adjustment and will disclose the decision the following trading day [7].

Group 1 - Baiya Co., Ltd. achieved a net profit of 188 million yuan in the first half of 2025, a year-on-year increase of 4.64% [1] - The company reported an operating income of 1.764 billion yuan, up 15.12% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2 - Leike Defense reported a net loss of 41.67 million yuan in the first half of 2025, compared to a loss of 66.43 million yuan in the same period last year [2] - The company achieved an operating income of 542 million yuan, a year-on-year increase of 9.77% [2] - Basic earnings per share were -0.03 yuan [2] Group 3 - Jinggong Technology achieved a net profit of 113 million yuan in the first half of 2025, a year-on-year increase of 15.55% [3] - The company reported an operating income of 1.061 billion yuan, up 10.31% year-on-year [3] - Basic earnings per share were 0.22 yuan [3] Group 4 - Yuejian Intelligent reported a net profit of 62.63 million yuan in the first half of 2025, a year-on-year increase of 46.99% [4] - The company achieved an operating income of 651 million yuan, up 13.22% year-on-year [4] - Basic earnings per share were 0.2436 yuan [4] Group 5 - Wanwei High-tech achieved a net profit of 256 million yuan in the first half of 2025, a year-on-year increase of 97.47% [6] - The company reported an operating income of 4.061 billion yuan, up 4.90% year-on-year [6] - Basic earnings per share were 0.122 yuan [6] Group 6 - Keli Equipment achieved a net profit of 82.78 million yuan in the first half of 2025, a year-on-year increase of 4.88% [7] - The company reported an operating income of 318 million yuan, up 12.41% year-on-year [7] - Basic earnings per share were 0.87 yuan [7] Group 7 - Jinwo Co., Ltd. achieved a net profit of 25.47 million yuan in the first half of 2025, a year-on-year increase of 94% [8] - The company reported an operating income of 614 million yuan, up 7.96% year-on-year [8] - Basic earnings per share were 0.21 yuan [8] Group 8 - Longyuan Technology achieved a net profit of 28.28 million yuan in the first half of 2025, a year-on-year increase of 135.6% [10] - The company reported an operating income of 362 million yuan, up 1.48% year-on-year [10] - Basic earnings per share were 0.0548 yuan [10] Group 9 - Guangting Information achieved a net profit of 42.92 million yuan in the first half of 2025, turning from loss to profit [13] - The company reported an operating income of 275 million yuan, up 26.88% year-on-year [13] - Basic earnings per share were 0.4633 yuan [13] Group 10 - Changjiang Materials achieved a net profit of 73.38 million yuan in the first half of 2025, a year-on-year increase of 5.03% [15] - The company reported an operating income of 513 million yuan, up 10.43% year-on-year [15] - Basic earnings per share were 0.5019 yuan [15] Group 11 - Yitong Century reported a net loss of 1.77 million yuan in the first half of 2025, compared to a profit of 35.87 million yuan in the same period last year [17] - The company achieved an operating income of 1.22 billion yuan, down 0.54% year-on-year [17] - Basic earnings per share were -0.0020 yuan [17] Group 12 - China Nuclear Construction signed new contracts worth 90.48 billion yuan in July 2025 [19] - The company achieved a cumulative operating income of 58.229 billion yuan [19] Group 13 - Yinlong Co., Ltd. signed a construction labor subcontracting contract worth 108 million yuan [21] - The contract is for the prefabrication of CRTSIII-type track slabs for a railway project [21] Group 14 - Xinan Century plans to apply for a comprehensive credit limit of no more than 50 million yuan from a bank [23] - The limit will be used for various business purposes including working capital loans [23] Group 15 - New Hongtai reported a net profit of 34.27 million yuan in the first half of 2025, a year-on-year decrease of 8.94% [25] - The company achieved an operating income of 308 million yuan, down 2.45% year-on-year [25] - Basic earnings per share were 0.23 yuan [25] Group 16 - Botong Co., Ltd. achieved a net profit of 13.33 million yuan in the first half of 2025, a year-on-year increase of 42.95% [26] - The company reported an operating income of 149 million yuan, up 5.23% year-on-year [26] - Basic earnings per share were 0.2135 yuan [26] Group 17 - Minfeng Special Paper reported a net profit of 15.07 million yuan in the first half of 2025, a year-on-year decrease of 68.88% [28] - The company achieved an operating income of 601 million yuan, down 23.21% year-on-year [28] - Basic earnings per share were 0.043 yuan [28] Group 18 - Changchun Yidong announced that a shareholder plans to reduce their stake by up to 2.97% [29] - The reduction period is from September 8, 2025, to December 5, 2025 [29] Group 19 - Jiukang Bio received an invention patent certificate for a reagent [30] - The patent involves the application of a specific enzyme in diagnostic reagents [30] Group 20 - Xuelang Environment announced the resignation of its general manager due to personal reasons [31] - The chairman will temporarily take over the general manager's responsibilities [31] Group 21 - Tailin Bio's subsidiary obtained a property certificate for industrial land [32] - The land area is 20,500 square meters with a usage period until July 6, 2075 [32] Group 22 - Changgao Electric New's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [33] Group 23 - Tianyoude Wine plans to use up to 147 million yuan of idle funds for cash management [34] Group 24 - Lingxiao Pump Industry used 5.9 million yuan of idle funds to purchase financial products [36] Group 25 - Mengke Pharmaceutical announced that a shareholder plans to reduce their stake by up to 3% [38] Group 26 - Kexiang Co., Ltd. plans to raise no more than 300 million yuan through a simplified procedure [40] Group 27 - Huagong Technology achieved a net profit of 911 million yuan in the first half of 2025, a year-on-year increase of 44.87% [42] - The company reported an operating income of 7.629 billion yuan, up 44.66% year-on-year [42] - Basic earnings per share were 0.91 yuan [42] Group 28 - Shanghai Jianke achieved a net profit of 23.76 million yuan in the first half of 2025, a year-on-year increase of 48.57% [43] - The company reported an operating income of 1.935 billion yuan, up 0.60% year-on-year [43] - Basic earnings per share were 0.06 yuan [43] Group 29 - Darui Electronics achieved a net profit of 132 million yuan in the first half of 2025, a year-on-year increase of 25.32% [44] - The company reported an operating income of 1.405 billion yuan, up 28.04% year-on-year [44] - Basic earnings per share were 1.00 yuan [44] Group 30 - Dongyangguang achieved a net profit of 613 million yuan in the first half of 2025, a year-on-year increase of 170.57% [45] - The company reported an operating income of 7.124 billion yuan, up 18.48% year-on-year [45] - Basic earnings per share were 0.209 yuan [45] Group 31 - Chongqing Beer reported a net profit of 865 million yuan in the first half of 2025, a year-on-year decrease of 4.03% [49] - The company achieved an operating income of 8.839 billion yuan, down 0.24% year-on-year [49] - Basic earnings per share were 1.79 yuan [49] Group 32 - Chongqing Beer announced that its subsidiary plans to increase capital by 600 million yuan [51] Group 33 - Meixin Technology announced that a shareholder plans to reduce their stake by up to 3% [53] Group 34 - Qipai Technology plans to raise no more than 159 million yuan through a private placement [55] Group 35 - Qipai Technology reported a net loss of 586.69 million yuan in the first half of 2025 [57] - The company achieved an operating income of 326 million yuan, up 4.09% year-on-year [57] - Basic earnings per share were -0.55 yuan [57] Group 36 - Huaying Technology reported a net loss of 476 million yuan in the first half of 2025 [59] - The company achieved an operating income of 721 million yuan, down 16.59% year-on-year [59] - Basic earnings per share were -0.1723 yuan [59] Group 37 - Best reported a net profit of 148 million yuan in the first half of 2025, a year-on-year increase of 3.30% [61] - The company achieved an operating income of 716 million yuan, up 2.73% year-on-year [61] - Basic earnings per share were 0.2966 yuan [61] Group 38 - Changliang Technology reported a net loss of 19.11 million yuan in the first half of 2025 [62] - The company achieved an operating income of 664 million yuan, down 5.64% year-on-year [62] - Basic earnings per share were -0.0236 yuan [62] Group 39 - Shunhao Co., Ltd. plans to use up to 35 million yuan of idle funds for entrusted wealth management [64] Group 40 - Weihede achieved a net profit of 65.97 million yuan in the first half of 2025, a year-on-year increase of 24.69% [66] - The company reported an operating income of 356 million yuan, up 38.37% year-on-year [66] - Basic earnings per share were 0.49 yuan [66] Group 41 - Huafa Co., Ltd. reported a net profit of 172 million yuan in the first half of 2025, a year-on-year decrease of 86.41% [67] - The company achieved an operating income of 38.199 billion yuan, up 53.46% year-on-year [67] - Basic earnings per share were 0.06 yuan [67] Group 42 - Mankun Technology achieved a net profit of 632 million yuan in the first half of 2025, a year-on-year increase of 62.30% [68] - The company reported an operating income of 760 million yuan, up 31.56% year-on-year [68] - Basic earnings per share were 0.43 yuan [68] Group 43 - Kelu Electronics achieved a net profit of 190 million yuan in the first half of 2025, turning from loss to profit [69] - The company reported an operating income of 2.573 billion yuan, up 34.66% year-on-year [69] - Basic earnings per share were 0.1144 yuan [69] Group 44 - Sanrenxing achieved a net profit of 144 million yuan in the first half of 2025, a year-on-year increase of 10.83% [71] - The company reported an operating income of 1.657 billion yuan, down 13.36% year-on-year [71] - Basic earnings per share were 0.68 yuan [71] Group 45 - Xinwei Communication achieved a net profit of 162 million yuan in the first half of 2025, a year-on-year decrease of 20.18% [72] - The company reported an operating income of 3.703 billion yuan, down 1.15% year-on-year [72] - Basic earnings per share were 0.1699 yuan [72] Group 46 - Yifan Pharmaceutical achieved a net profit of 304 million yuan in the first half of 2025, a year-on-year increase of 19.91% [72] - The company reported an operating income of 2.635 billion yuan, up 0.11% year-on-year [72] - Basic earnings per share were 0.25 yuan [72] Group 47 - *ST Chengchang achieved a net profit of 566 million yuan in the first half of 2025, turning from loss to profit [73] - The company reported an operating income of 201 million yuan, up 180.16% year-on-year [73] - Basic earnings per share were 0.2783 yuan [73] Group 48 - Rejing Bio announced that a controlling shareholder plans to reduce their stake by up to 1.08% [74] Group 49 - Jingu Co., Ltd. signed a strategic cooperation framework agreement with Luming Robotics [75]

Group 1 - The core point of the article is that Kehua Bio has received a medical device registration certificate from the National Medical Products Administration for its product "Treponema pallidum antibody quality control product" [2] - Kehua Bio's revenue composition for the year 2024 is expected to be 100.0% from the biopharmaceutical industry [2]

Core Viewpoint - The company Kewah Bio (002022) has received a medical device registration certificate from the National Medical Products Administration for a quality control product related to syphilis testing [1] Group 1 - The product is named "Syphilis Treponema Antibody Quality Control Product" [1] - This product is used in conjunction with the company's "Syphilis Treponema Antibody (Anti-TP) Test Kit" which employs a chemiluminescence method [1] - The purpose of the product is to ensure quality control for the syphilis treponema antibody detection project [1]

关于"科华转债"预计触发 | 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-039 | 上海科华生物工程股份有限公司 (二) 可转债转股期限 转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 4、转股时间：2021 年 2 月 3 日至 2026 年 7 月 27 日 5、根据《上海科华生物工程股份有限公司公开发行可转换公司债券募集说 明书》（以下简称"《募集说明书》"）的规定，在上海科华生物工程股份有限公司 （以下简称"公司"）本次发行的可转债存续期间，当公司股票在任意连续 20 个 交易日中至少有 10 个交易日的收盘价低于当期转股价格的 90%时，公司董事会 有权提出转股价格向下修正方案并提交公司股东大会表决。本次触发转股价格 修正条件的期间从 2025 年 8 月 11 日起算，自 2025 年 8 月 11 日至 2025 年 8 月 15 日，公司股票已有 5 个交易日的收盘价低于 ...

上海科华生物工程股份有限公司 关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的医疗器械注册证（体外诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 本产品配套本公司梅毒螺 | | --- | --- | --- | --- | --- | | | 梅毒螺旋体 | 国械注准 | 2025年08月14日 | 旋体抗体（Anti-TP）检测 | | 1 | 抗体质控品 | 20253401546 | 至 | 试剂盒（化学发光法）使用， | | | | | 2030年08月13日 | 用于梅毒螺旋体抗体（Anti | | | | | | TP）检测项目的质量控制。 | 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 | 证券代码：002022 | 证券简称：科华生物 公告 ...